Document
false--12-31Q1201900014381330P2YP4YP6MP4YP5YFour Six-MonthP1YP2YP2YP2YP1YP2YP2YP1Y3.5046300000.0010.0012000000002000000005939600060071000593960006007100031000004700000230000065000001240000000.750.75 0001438133 2020-01-01 2020-03-31 0001438133 2020-04-21 0001438133 2020-03-31 0001438133 2019-12-31 0001438133 2019-01-01 2019-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001438133 us-gaap:CommonStockMember 2019-12-31 0001438133 us-gaap:CommonStockMember 2020-03-31 0001438133 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001438133 us-gaap:RetainedEarningsMember 2019-12-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001438133 us-gaap:RetainedEarningsMember 2020-03-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001438133 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001438133 2019-03-31 0001438133 us-gaap:CommonStockMember 2018-12-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001438133 2018-12-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001438133 us-gaap:RetainedEarningsMember 2018-12-31 0001438133 us-gaap:CommonStockMember 2019-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001438133 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001438133 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001438133 us-gaap:RetainedEarningsMember 2019-03-31 0001438133 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001438133 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001438133 tndm:InsulinPumpMember srt:MinimumMember 2020-01-01 2020-03-31 0001438133 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001438133 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001438133 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001438133 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001438133 us-gaap:EmployeeStockMember 2019-01-01 2019-03-31 0001438133 us-gaap:EmployeeStockMember 2020-01-01 2020-03-31 0001438133 us-gaap:TransferredOverTimeMember 2019-12-31 0001438133 us-gaap:TransferredOverTimeMember 2020-03-31 0001438133 us-gaap:WarrantyReservesMember 2020-03-31 0001438133 tndm:ComplementaryProductsMember 2020-01-01 2020-03-31 0001438133 tndm:TandemPumpMember 2020-01-01 2020-03-31 0001438133 tndm:SlimCartridgesAndInfusionSetsMember 2020-01-01 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember 2019-12-31 0001438133 us-gaap:CommercialPaperMember 2019-12-31 0001438133 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-12-31 0001438133 us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-03-31 0001438133 us-gaap:USTreasurySecuritiesMember 2020-03-31 0001438133 us-gaap:CommercialPaperMember 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember 2020-03-31 0001438133 srt:MaximumMember us-gaap:CommercialPaperMember 2020-01-01 2020-03-31 0001438133 srt:MaximumMember us-gaap:CommercialPaperMember 2019-01-01 2019-12-31 0001438133 srt:MaximumMember us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0001438133 srt:MaximumMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2020-01-01 2020-03-31 0001438133 srt:MaximumMember us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember 2019-01-01 2019-12-31 0001438133 srt:MaximumMember us-gaap:USTreasurySecuritiesMember 2020-01-01 2020-03-31 0001438133 srt:MaximumMember us-gaap:CorporateDebtSecuritiesMember 2019-01-01 2019-12-31 0001438133 srt:MaximumMember us-gaap:USTreasurySecuritiesMember 2019-01-01 2019-12-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2019-12-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2019-12-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-12-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2019-12-31 0001438133 tndm:SeriesAWarrantsMember 2019-03-31 0001438133 tndm:SeriesAWarrantsMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember 2020-01-01 2020-03-31 0001438133 tndm:SeriesAWarrantsMember tndm:SecondaryPublicOfferingMember 2020-01-01 2020-03-31 0001438133 tndm:SeriesAWarrantsMember tndm:SecondaryPublicOfferingMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember 2017-10-31 0001438133 srt:MaximumMember 2020-01-01 2020-03-31 0001438133 tndm:SeriesAWarrantsMember 2019-01-01 2019-03-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:WarrantMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001438133 tndm:SeriesAWarrantsMember tndm:SecondaryPublicOfferingMember 2019-12-31 0001438133 tndm:SeriesAWarrantsMember tndm:SecondaryPublicOfferingMember 2019-01-01 2019-12-31 0001438133 tndm:VistaSorrentoParkwayLeaseMember 2019-03-31 0001438133 srt:MaximumMember tndm:VistaSorrentoParkwayLeaseMember 2020-03-31 0001438133 tndm:HighBluffDriveSanDiegoCaliforniaMember 2020-01-31 0001438133 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001438133 tndm:ShorelineDriveBoiseIdahoMember 2019-11-30 0001438133 us-gaap:AccountingStandardsUpdate201602Member us-gaap:OtherCurrentLiabilitiesMember tndm:DifferenceBetweenLeasesGuidanceInEffectBeforeAndAfterTopic842Member 2019-01-01 0001438133 tndm:VistaSorrentoParkwayLeaseMember 2019-01-31 0001438133 tndm:VistaSorrentoParkwayLeaseMember tndm:VistaSorrentoLeaseMember 2019-03-31 0001438133 tndm:VistaSorrentoParkwayLeaseMember 2019-05-31 0001438133 tndm:HighBluffDriveSanDiegoCaliforniaMember 2020-03-31 0001438133 tndm:ShorelineDriveBoiseIdahoMember 2020-03-31 0001438133 us-gaap:AccountingStandardsUpdate201602Member tndm:DifferenceBetweenLeasesGuidanceInEffectBeforeAndAfterTopic842Member 2019-01-01 0001438133 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001438133 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001438133 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001438133 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0001438133 us-gaap:CostOfSalesMember 2020-01-01 2020-03-31 0001438133 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-03-31 0001438133 us-gaap:CostOfSalesMember 2019-01-01 2019-03-31 0001438133 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001438133 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001438133 tndm:TwoThousandThirteenPlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-06-01 2019-06-30 0001438133 tndm:CommonStockWarrantExpiringMarch2027Member 2020-03-31 0001438133 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001438133 tndm:TwoThousandThirteenPlanMember 2020-01-01 2020-03-31 0001438133 tndm:CommonStockWarrantExpiringBetweenAugust2021andAugust2022Member 2020-03-31 0001438133 us-gaap:WarrantMember 2019-01-01 2019-03-31 0001438133 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001438133 2018-01-01 2018-12-31 0001438133 tndm:TwoThousandThirteenPlanMember 2019-01-01 2019-03-31 0001438133 tndm:ContingentEmployeeStockOptionsMember 2019-01-01 2019-03-31 0001438133 us-gaap:StockCompensationPlanMember 2020-03-31 0001438133 us-gaap:GrantMember 2020-03-31 0001438133 tndm:StockOptionsIssuedAndOutstandingMember 2020-03-31 0001438133 us-gaap:WarrantMember 2020-03-31 0001438133 tndm:TwoThousandThirteenPlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0001438133 tndm:TwoThousandThirteenPlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-01-01 2020-03-31 0001438133 2019-01-01 2019-12-31 xbrli:shares iso4217:USD xbrli:shares tndm:legal_matter iso4217:USD utreg:sqft tndm:segment xbrli:pure

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________________________________________
FORM 10-Q
_____________________________________________________________________________________________
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2020
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Transition Period from              to                 
Commission File Number 001-36189
_____________________________________________________________________________________________
Tandem Diabetes Care, Inc.
(Exact name of registrant as specified in its charter)
_____________________________________________________________________________________________
Delaware
 
20-4327508
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
11075 Roselle Street
 
92121
San Diego,
California
 
(Zip Code)
(Address of principal executive offices)
 
 
(858) 366-6900
Registrant’s telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Symbol
Name of Exchange on Which Registered
Common Stock, par value $0.001 per share
TNDM
NASDAQ Global Market
_____________________________________________________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
 
Accelerated filer
Non-accelerated filer
 
Smaller reporting company
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of April 21, 2020, there were 60,102,978 shares of the registrant’s Common Stock outstanding.
 



TABLE OF CONTENTS
 
 
 
 
 
 
 
 



PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
 
March 31,
 
December 31,
 
2020
 
2019
 
(Unaudited)
 
(Note 1)
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
74,485

 
$
51,175

Short-term investments
85,723

 
125,283

Accounts receivable, net
53,962

 
46,585

Inventories
60,469

 
49,073

Prepaid and other current assets
6,234

 
4,025

Total current assets
280,873

 
276,141

Property and equipment, net
37,626

 
32,923

Operating lease right-of-use assets
23,014

 
15,561

Other long-term assets
1,814

 
1,485

Total assets
$
343,327

 
$
326,110

Liabilities and Stockholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
21,783

 
$
17,745

Accrued expenses
5,896

 
8,014

Employee-related liabilities
22,059

 
28,320

Deferred revenue
4,377

 
3,869

Common stock warrants
25,290

 
23,509

Operating lease liabilities
8,320

 
6,320

Other current liabilities
11,922

 
11,619

Total current liabilities
99,647

 
99,396

Operating lease liabilities - long-term
19,547

 
14,063

Other long-term liabilities
16,957

 
17,672

Total liabilities
136,151

 
131,131

Commitments and contingencies (Note 9)


 


Stockholders’ equity:
 
 
 
Common stock, $0.001 par value; 200,000 shares authorized, 60,071 and 59,396 shares issued and outstanding at March 31, 2020 (unaudited) and December 31, 2019, respectively.
60

 
59

Additional paid-in capital
847,056

 
819,626

Accumulated other comprehensive income (loss)
(245
)
 
122

Accumulated deficit
(639,695
)
 
(624,828
)
Total stockholders’ equity
207,176

 
194,979

Total liabilities and stockholders’ equity
$
343,327

 
$
326,110

See accompanying notes to unaudited condensed consolidated financial statements.

1


TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except per share data)
 
Three Months Ended March 31,
 
2020
 
2019
Sales
$
97,926

 
$
65,995

Cost of sales
47,665

 
32,642

Gross profit
50,261

 
33,353

Operating expenses:
 
 
 
Selling, general and administrative
49,717

 
34,961

Research and development
14,117

 
9,389

Total operating expenses
63,834

 
44,350

Operating loss
(13,573
)
 
(10,997
)
Other income (expense), net:
 
 
 
Interest and other income
726

 
757

Interest and other expense

 
(6
)
Change in fair value of common stock warrants
(1,922
)
 
(12,746
)
Total other expense, net
(1,196
)
 
(11,995
)
Loss before income taxes
(14,769
)
 
(22,992
)
Income tax expense
98

 

Net loss
$
(14,867
)
 
$
(22,992
)
Other comprehensive loss:
 
 
 
Unrealized gain on short-term investments
$
42

 
$
50

Foreign currency translation gain (loss)
(409
)
 
4

Comprehensive loss
$
(15,234
)
 
$
(22,938
)
 
 
 
 
Net loss per share, basic and diluted
$
(0.25
)
 
$
(0.40
)
Weighted average shares used to compute basic and diluted net loss per share
59,740

 
57,771

See accompanying notes to unaudited condensed consolidated financial statements.

2


TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands)

Three Months Ended March 31, 2020
 
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Total
Stockholders’
Equity
 
Shares
 
Amount
Balance at December 31, 2019
59,396

 
$
59

 
$
819,626

 
$
122

 
$
(624,828
)
 
$
194,979

Exercise of stock options
673

 
1

 
11,474

 

 

 
11,475

Exercise of common stock warrants
2

 

 
7

 

 

 
7

Fair value of common stock warrants at time of exercise

 

 
141

 

 

 
141

Stock-based compensation

 

 
15,808

 

 

 
15,808

Unrealized gain on short-term investments, net of deferred tax

 

 

 
42

 

 
42

Foreign currency translation adjustments

 

 

 
(409
)
 

 
(409
)
Net loss

 

 

 

 
(14,867
)
 
(14,867
)
Balance at March 31, 2020
60,071

 
$
60

 
$
847,056

 
$
(245
)
 
$
(639,695
)
 
$
207,176


Three Months Ended March 31, 2019
 
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Total
Stockholders’
Equity
 
Shares
 
Amount
Balance at December 31, 2018
57,554

 
$
57

 
$
731,306

 
$
(13
)
 
$
(600,075
)
 
$
131,275

Exercise of stock options
409

 
1

 
1,898

 

 

 
1,899

Exercise of common stock warrants
19

 

 
64

 

 

 
64

Fair value of common stock warrants at time of exercise

 

 
910

 

 

 
910

Stock-based compensation

 

 
9,752

 

 

 
9,752

Unrealized gain on short-term investments

 

 

 
50

 

 
50

Foreign currency translation adjustments

 

 

 
4

 

 
4

Net loss

 

 

 

 
(22,992
)
 
(22,992
)
Balance at March 31, 2019
57,982

 
$
58

 
$
743,930

 
$
41

 
$
(623,067
)
 
$
120,962

See accompanying notes to unaudited condensed consolidated financial statements.


3


TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
Three Months Ended March 31,
 
2020
 
2019
Operating Activities
 
 
 
Net loss
$
(14,867
)
 
$
(22,992
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization expense
1,830

 
1,438

Provision for expected credit losses
862

 
342

Provision (benefit) for inventory obsolescence
(363
)
 
679

Change in fair value of common stock warrants
1,922

 
12,746

Amortization of discount on short-term investments
(66
)
 
(94
)
Stock-based compensation expense
15,865

 
9,834

Other
19

 
27

Changes in operating assets and liabilities:
 
 
 
Accounts receivable, net
(8,292
)
 
1,821

Inventories, net
(11,095
)
 
(3,690
)
Prepaid and other current assets
(2,231
)
 
(1,036
)
Other long-term assets
(383
)
 
(225
)
Accounts payable
4,294

 
4,376

Accrued expenses
(2,124
)
 
(553
)
Employee-related liabilities
(6,253
)
 
(6,982
)
Deferred revenue
1,524

 
861

Other current liabilities
431

 
(2,120
)
Other long-term liabilities
(1,704
)
 
1,444

Net cash used in operating activities
(20,631
)
 
(4,124
)
Investing Activities
 
 
 
Purchases of short-term investments
(9,727
)
 
(42,914
)
Proceeds from maturities of short-term investments
30,859

 
43,700

Proceeds from sales of short-term investments
18,550

 
1,400

Purchases of property and equipment
(6,766
)
 
(1,408
)
Net cash provided by investing activities
32,916

 
778

Financing Activities
 
 
 
Proceeds from exercise of common stock warrants
7

 
64

Proceeds from issuance of common stock under Company stock plans
11,474

 
1,898

Net cash provided by financing activities
11,481

 
1,962

Effect of foreign exchange rate changes on cash
(456
)
 
3

Net increase (decrease) in cash and cash equivalents
23,310

 
(1,381
)
Cash and cash equivalents at beginning of period
51,175

 
41,826

Cash and cash equivalents at end of period
$
74,485

 
$
40,445

Supplemental disclosures of cash flow information
 
 
 
Income taxes paid
$
91

 
$

Supplemental schedule of non-cash investing and financing activities
 
 
 
Right-of-use assets obtained in exchange for operating lease obligations
$
8,805

 
$
3,053

Property and equipment included in accounts payable
$
1,880

 
$
130

See accompanying notes to unaudited condensed consolidated financial statements.

4


TANDEM DIABETES CARE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Organization and Basis of Presentation
The Company
Tandem Diabetes Care, Inc. is a medical device company with an innovative approach to the design, development and commercialization of products for people with insulin-dependent diabetes. The Company is incorporated in the state of Delaware. Unless the context requires otherwise, the terms the “Company” or “Tandem” refer to Tandem Diabetes Care, Inc., together with its wholly-owned subsidiary in Canada.
The Company manufactures, sells and supports insulin pump products that are designed to address the evolving needs and preferences of differentiated segments of the insulin-dependent diabetes market. The Company’s manufacturing, sales and support activities principally focus on the t:slim X2 Insulin Delivery System (t:slim X2), the Company’s flagship pump platform which is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. The Company’s insulin pump products are compatible with the t:connect cloud-based data management application (t:connect) and the Tandem Device Updater, a Mac and PC-compatible tool for the remote update of the Company’s insulin pump software. The Company’s insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, the Company sells disposable products that are used together with the pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body.
The Company has commercially launched seven insulin pumps in the United States since 2012 and two pumps outside the United States since 2018. Four of the insulin pumps have featured integration with CGM technology, of which two have also featured an automated insulin delivery (AID) algorithm. In June 2018, the t:slim X2 was the first insulin pump designated as compatible with integrated CGM (iCGM) devices; in February 2019, the t:slim X2 was the first insulin pump in a new device category called Alternate Controller Enabled Infusion Pumps (ACE pumps); and in December 2019, Control-IQ technology for the t:slim X2 insulin pump was the first automated insulin dosing software in a new interoperable automated glycemic controller category. The Company believes that the three new classifications by the United States Food and Drug Administration (FDA) for the interoperability of devices for AID will help support continued rapid innovation by streamlining the regulatory pathway for integrated products.
As of March 31, 2020, the Company had $160.2 million in cash and cash equivalents and short-term investments. The Company has incurred operating losses since its inception and had an accumulated deficit of $639.7 million as of March 31, 2020, which included a net loss of $14.9 million for the three months ended March 31, 2020. Management believes that the cash, cash equivalents and short-term investments on hand will be sufficient to satisfy the Company’s liquidity requirements for at least the next 12 months from the date of this filing.
The Company’s ability to execute on its business strategy, meet its future liquidity requirements, and achieve and maintain profitable operations, is dependent on a number of factors, including its ability to continue to gain market acceptance of its products and achieve a level of revenues adequate to support its cost structure, achieve renewal pump sales objectives, develop and launch new products, expand the commercialization of products into new international markets, maximize manufacturing efficiencies, satisfy increasing production requirements, leverage the investments made in its sales, clinical, marketing and customer support organizations, and operate its business and manufacture and sell products without infringing on third-party intellectual property rights.
The Company has funded its operations primarily through cash collected from product sales, private and public offerings of equity securities, and through debt financing which has since been fully repaid. The Company may in the future seek additional capital from public or private offerings of equity or debt securities, or it may elect to borrow capital under new credit arrangements or from other sources. If the Company issues equity or debt securities to raise additional funds, its existing stockholders may experience dilution, it may incur significant financing or debt service costs, and the new equity or debt securities may have rights, preferences and privileges senior to those of its existing stockholders. There can be no assurance that equity or debt financing will be available on acceptable terms, or at all.

5


Basis of Presentation and Principles of Consolidation
The Company has prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments which are of a normal and recurring nature, considered necessary for a fair presentation of the financial information contained herein, have been included.
Interim financial results are not necessarily indicative of results anticipated for the full year or any other period(s). These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 (Annual Report), from which the balance sheet information herein was derived.
The condensed consolidated financial statements include the accounts of Tandem Diabetes Care, Inc. and its wholly owned subsidiary in Canada. All significant intercompany balances and transactions have been eliminated in consolidation.
The functional currency of our foreign subsidiary is the local currency. The Company translates the financial statements of its foreign subsidiary into U.S. dollars using period-end exchange rates for assets and liabilities and average exchange rates for each period for revenue, costs and expenses. Translation related adjustments are included in comprehensive loss and in accumulated other comprehensive income (loss) in the equity section of the Company’s condensed consolidated balance sheets. Foreign exchange gains or losses resulting from balances denominated in a currency other than the functional currency are recognized in interest and other income or interest and other expense in the Company’s condensed consolidated statements of operations.
Reclassification
Prior year amounts related to the presentation of proceeds from maturities and sales of short-term investments on the Company’s condensed consolidated statement of cash flows, have been reclassified to conform to the current year presentation.
2. Summary of Significant Accounting Policies
There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2020, as compared to those disclosed in the Annual Report.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes as of the date of the consolidated financial statements. Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions or conditions.
Segment Reporting
Operating segments are identified as components of an enterprise about which discrete financial information is available for evaluation by the chief operating decision-maker (CODM) in making decisions regarding resource allocation and assessing performance. The Company is organized based on its current product portfolio, which consists primarily of insulin pumps, disposable cartridges and infusion sets for the storage and delivery of insulin. The Company views its operations and manages its business as one segment because key operating decisions and resource allocations are made by the CODM using consolidated financial data.

6


Accounts Receivable
The Company grants credit to various customers in the ordinary course of business and is paid directly by customers who use the products, distributors and third-party insurance payors. The Company maintains an allowance for its current estimate of expected credit losses. Provisions for expected credit losses are estimated based on historical experience, assessment of specific risk, review of outstanding invoices, forecasts about the future, and various assumptions and estimates that are believed to be reasonable under the circumstances. Uncollectible accounts are written off against the allowance after appropriate collection efforts have been exhausted and when it is deemed that a balance is uncollectible.
Fair Value of Financial Instruments
The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and employee-related liabilities are reasonable estimates of their fair values because of the short-term nature of these assets and liabilities. Short-term investments are carried at fair value. The Company believes the fair value of its operating lease liabilities at March 31, 2020 approximated their carrying value, based on the borrowing rates that were available for loans with similar terms as of that date. The estimated fair value of certain of the Company’s common stock warrants was determined using the Black-Scholes pricing model as of March 31, 2020 and December 31, 2019 (see Note 5, “Fair Value Measurements”).
Operating Lease Right-of-Use Assets and Liabilities
Lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent their obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (the Commencement Date) based on the present value of lease payments over the lease term. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the Company’s consolidated balance sheet. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets, and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the consolidated balance sheets (see Note 6, “Leases”).
Revenue Recognition
Revenue is generated primarily from sales of insulin pumps, disposable cartridges and infusion sets to individual customers and third-party distributors that resell the products to insulin-dependent diabetes customers. The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.
Revenue Recognition for Arrangements with Multiple Deliverables
The Company considers the individual deliverables in its product offering as separate performance obligations. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company allocates the consideration to the individual performance obligations and recognizes the consideration based on when the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. Generally, insulin pumps, cartridges, infusion sets and accessories are deemed performance obligations that are satisfied at a point in time when the customer obtains control of the promised good, which is upon delivery. Complementary products, such as t:connect and the Tandem Device Updater, are considered performance obligations that are satisfied over time, as access and support for these products is provided throughout the typical four-year warranty period of the insulin pumps. Accordingly, revenue related to the complementary products is deferred and recognized ratably over a four-year period. There is no standalone value for these complementary products. Therefore, the Company determines their value by applying the expected cost plus a margin approach and then allocates the residual to the insulin pumps. Deferred revenue related to these performance obligations that are satisfied over time was included in the following consolidated balance sheet accounts in the amounts shown as of March 31, 2020 and December 31, 2019 (in thousands):

7


 
March 31, 2020
 
December 31, 2019
Deferred revenue
$
3,833

 
$
3,465

Other long-term liabilities
6,626

 
5,656

Total
$
10,459

 
$
9,121


Sales Returns
The Company offers a 30-day right of return to customers in the U.S. and Canada from the date of shipment of its insulin pumps, provided a physician’s confirmation of the medical reason for the return is received. Estimated allowances for sales returns are based on historical returned quantities as compared to pump shipments in those same periods of return. The return rate is then applied to the sales of the current period to establish a reserve at the end of the period. The return rates used in the reserve are adjusted for known or expected changes in the marketplace when appropriate. The allowance for sales returns is recorded as a reduction of revenue and an increase in deferred revenue in the period in which the related sale is recorded. The amount recorded in deferred revenue on the Company’s consolidated balance sheets for allowances for sales returns was $0.5 million and $0.4 million at March 31, 2020 and December 31, 2019, respectively. Actual product returns have not differed materially from estimated amounts recorded in the accompanying condensed consolidated financial statements.
Warranty Reserve
The Company generally provides a four-year warranty on its insulin pumps to end-user customers and may replace any pumps that do not function in accordance with the product specifications. Insulin pumps returned to the Company may be refurbished and redeployed. Additionally, the Company offers a six-month warranty on disposable cartridges and infusion sets. Estimated warranty costs are recorded at the time of shipment. We evaluate the reserve quarterly. Warranty costs are primarily estimated based on the current expected product replacement cost and expected replacement rates utilizing historical experience. Recently released versions of the pump may not incur warranty costs in a manner similar to previously released pumps, on which the Company initially bases its warranty estimate of newer pumps. The Company may make further adjustments to the warranty reserve when deemed appropriate, giving additional consideration to length of time the pump version has been in the field and future expectations of performance based on new features and capabilities that may become available through Tandem Device Updater.
The following table provides a reconciliation of the change in product warranty liabilities from December 31, 2019 through March 31, 2020 (in thousands):
Balance at December 31, 2019
$
16,724

Provision for warranties issued during the period
4,814

Settlements made during the period
(3,390
)
Decreases in warranty estimates
(1,387
)
Balance at March 31, 2020
$
16,761

As of March 31, 2020 and December 31, 2019, total product warranty reserves of $16.8 million and $16.7 million, respectively, were included in the following consolidated balance sheet accounts (in thousands):
 
March 31, 2020
 
December 31, 2019
Other current liabilities
$
6,427

 
$
4,707

Other long-term liabilities
10,334

 
12,017

Total warranty reserves
$
16,761

 
$
16,724



8


Stock-Based Compensation
Stock-based compensation cost is measured at the grant date based on the estimated fair value of the award, and the portion that is ultimately expected to vest is recognized as compensation expense over the requisite service period on a straight-line basis. The Company estimates the fair value of stock options issued under the Company’s Amended and Restated 2013 Stock Incentive Plan (2013 Plan), and the fair value of the employees’ purchase rights under the Company’s 2013 Employee Stock Purchase Plan (ESPP), using the Black-Scholes option-pricing model on the date of grant. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, including stock price volatility, expected term, dividend yield and risk-free interest rate (see Note 7, “Stockholders’ Equity”). For awards that vest based on the achievement of service conditions, the Company recognizes expense using the straight-line method less estimated forfeitures based on historical experience.
Net Loss Per Share
Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares that were outstanding for the period, without consideration for common stock equivalents. Diluted loss per share is calculated in accordance with the treasury stock method and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. Dilutive common share equivalents are comprised of warrants, potential awards granted pursuant to the ESPP, and stock options outstanding under the Company’s equity incentive plans. For warrants that are recorded as a liability in the accompanying condensed consolidated balance sheets, the calculation of diluted loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the warrants and the presumed exercise of the warrants is dilutive to loss per share for the period, an adjustment is made to net loss used in the calculation to remove the change in fair value of the warrants from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any, under the treasury stock method. For the three months ended March 31, 2020 and 2019, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position.
Potentially dilutive securities not included in the calculation of diluted net loss per share (because inclusion would be anti-dilutive) are as follows (in thousands, in common stock equivalent shares):
 
Three Months Ended
March 31,
 
2020
 
2019
Warrants to purchase common stock
609

 
686

Options to purchase common stock
5,710

 
5,475

Awards granted under the ESPP
198

 
142

 
6,517

 
6,303


Recent Accounting Pronouncements
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income (loss) rather than reducing the carrying amount under the prior, other-than-temporary-impairment model. The new standard must be adopted using the modified retrospective approach and was effective for the Company starting in the first quarter of fiscal 2020. The Company determined there was no cumulative-effect transition adjustment to the opening balance of accumulated deficit for recognition of additional credit losses upon adoption of this standard as of January 1, 2020 based on its outstanding accounts receivable, the composition and credit quality of its short-term investments, and current economic conditions as of that date.

9


In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The updated guidance was effective for the Company starting in the first quarter of fiscal 2020. As a result, the Company modified certain fair value measurement disclosures primarily related to its Level 3 liabilities (see Note 5, “Fair Value Measurements”).
In December 2019, the FASB issued ASU No. 2019-12, Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law. ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is in the process of assessing the impact of the adoption of the standard on its consolidated financial statements.
3. Short-Term Investments
The Company invests in marketable securities consisting of debt instruments of the U.S. Government, and financial institutions and corporations with strong credit ratings. The following represents a summary of the estimated fair value of short-term investments as of March 31, 2020 and December 31, 2019 (in thousands):
At March 31, 2020
Maturity
(in years)
 
Amortized
Cost
 
Gross Unrealized
Gain
 
Gross Unrealized
Loss
 
Estimated
Fair Value
Available-for-sale securities:
 
 
 
 
 
 
 
 
 
Commercial paper
Less than 1
 
$
17,352

 
$
11

 
$

 
$
17,363

U.S. Government-sponsored enterprise
Less than 2
 
20,255

 
63

 

 
20,318

U.S. Treasury securities
Less than 1
 
12,721

 
93

 

 
12,814

Corporate debt securities
Less than 2
 
35,251

 
39

 
(62
)
 
35,228

Total
 
 
$
85,579

 
$
206

 
$
(62
)
 
$
85,723

At December 31, 2019
Maturity
(in years)
 
Amortized
Cost
 
Gross Unrealized
Gain
 
Gross Unrealized
Loss
 
Estimated
Fair Value
Available-for-sale securities:
 
 
 
 
 
 
 
 
 
Commercial paper
Less than 1
 
$
24,147

 
$
10

 
$

 
$
24,157

U.S. Government-sponsored enterprise
Less than 2
 
33,073

 
26

 

 
33,099

U.S. Treasury securities
Less than 2
 
17,963

 
17

 
(1
)
 
17,979

Corporate debt securities
Less than 2
 
50,011

 
42

 
(5
)
 
50,048

Total
 
 
$
125,194

 
$
95

 
$
(6
)
 
$
125,283


The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company’s ability and intent to use any of those marketable securities to satisfy the Company’s liquidity requirements.

The Company periodically reviews the portfolio of available-for-sale debt securities to determine if any investment is impaired due to changes in credit risk or other potential valuation concerns. Unrealized losses on available-for-sale debt securities at March 31, 2020 were not significant and were due to changes in interest rates, including credit spreads from perceived increased credit risks as a result of the novel coronavirus (COVID-19) global pandemic. The Company does not intend to sell the available-for-sale debt securities that are in an unrealized loss position, and it is not more likely than not that the Company will be required to sell these debt securities before recovery of their amortized cost bases, which may be at maturity. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company’s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses. Accordingly, at March 31, 2020, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.

10



4. Accounts Receivable and Inventories

Accounts Receivable
Accounts receivable consisted of the following (in thousands):
 
March 31,
 
December 31,
 
2020
 
2019
Accounts receivable
$
57,346

 
$
49,889

Less allowance for credit losses
(3,384
)
 
(3,304
)
Accounts receivable, net
$
53,962

 
$
46,585


Allowance for Credit Losses
The following table provides a reconciliation of the change in the estimated allowance for expected accounts receivable credit losses for the three months ended March 31, 2020 and 2019 (in thousands):

 
 
For the Three Months Ended
 
 
March 31, 2020
 
March 31, 2019
Balance at beginning of the period
 
$
3,304

 
$
1,837

Provision for expected credit losses
 
862

 
342

Write-offs and adjustments, net of recoveries
 
(782
)
 
(163
)
Balance at end of the period
 
$
3,384

 
$
2,016


Inventories
Inventories consisted of the following as of March 31, 2020 and December 31, 2019 (in thousands):
 
March 31,
2020
 
December 31,
2019
Raw materials
$
31,795

 
$
20,699

Work-in-process
14,543

 
16,532

Finished goods
14,131

 
11,842

Inventories
$
60,469

 
$
49,073


5. Fair Value Measurements
Authoritative guidance on fair value measurements defines fair value, and provides a consistent framework for measuring fair value and for disclosures of each major asset and liability category measured at fair value on either a recurring or a nonrecurring basis. Fair value is intended to reflect an assumed exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
Level 1:
Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2:
Inputs, other than quoted prices in active markets, that are observable either directly or indirectly for substantially the full term of the asset or liability.

11


Level 3:
Unobservable inputs in which there is little or no market data and that are significant to the fair value of the assets or liabilities, which require the reporting entity to develop its own valuation techniques that require input assumptions.
The following table presents information about the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2020 and December 31, 2019, and indicates the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value (in thousands):  
 
 
 
Fair Value Measurements at
March 31, 2020
 
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets
 
 
 
 
 
 
 
Cash equivalents(1)
$
69,346

 
$
69,346

 
$

 
$

Commercial paper
17,363

 

 
17,363

 

U.S. Government-sponsored enterprise
20,318

 

 
20,318

 

U.S. Treasury securities
12,814

 
12,814

 

 

Corporate debt securities
35,228

 

 
35,228

 

Total assets
$
155,069

 
$
82,160

 
$
72,909

 
$

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Common stock warrants
$
25,290

 
$

 
$

 
$
25,290

Total liabilities
$
25,290

 
$

 
$

 
$
25,290

 
 
 
Fair Value Measurements at
December 31, 2019
 
 
(Level 1)
 
(Level 2)
 
(Level 3)
Assets
 
 
 
 
 
 
 
Cash equivalents(1)
$
49,077

 
$
49,077

 
$

 
$

Commercial paper
24,157

 

 
24,157

 

U.S. Government-sponsored enterprise
33,099

 

 
33,099

 

U.S. Treasury securities
17,979

 
17,979

 

 

Corporate debt securities
50,048

 

 
50,048

 

Total assets
$
174,360

 
$
67,056

 
$
107,304

 
$

 
 
 
 
 
 
 
 
Liabilities
 
 
 
 
 
 
 
Common stock warrants
$
23,509

 
$

 
$

 
$
23,509

Total liabilities
$
23,509

 
$

 
$

 
$
23,509

(1)
Generally, cash equivalents include money market funds and investments with a maturity of three months or less from the date of purchase.
The Company’s Level 2 financial instruments are valued using market prices on less active markets with observable valuation inputs such as interest rates and yield curves. The Company obtains the fair value of Level 2 financial instruments from quoted market prices, calculated prices or quotes from third-party pricing services. The Company validates these prices through independent valuation testing and review of portfolio valuations provided by the Company’s investment managers.
The Company’s Level 3 liabilities at March 31, 2020 and December 31, 2019 include the Series A warrants issued by the Company in connection with the public offering of common stock in October 2017. The Series A warrants have a term of five years and initially provided holders the right to purchase 4,630,000 shares of the Company’s common stock at an exercise price of $3.50 per share. The Series A warrants were initially valued in the aggregate amount of $5.2 million on the date of issuance utilizing a Black-Scholes pricing model.

12


The Company reassesses the fair value of the outstanding Series A warrants at each reporting date utilizing a Black-Scholes pricing model. Variables used in the pricing model include the closing market price of the Company’s common stock at the balance sheet date, and estimates of stock price volatility, dividend yield, expected warrant term and risk-free interest rate. The Company develops its estimates based on publicly available historical data. A significant increase (decrease) in any of these inputs in isolation, particularly the market price of the Company’s common stock, would have resulted in a significantly higher (lower) fair value measurement. The assumptions used to estimate the fair values of the outstanding Series A warrants at March 31, 2020 and December 31, 2019 are presented below:
 
March 31, 2020
 
December 31, 2019
Risk-free interest rate
0.3
%
 
1.6
%
Expected dividend yield
0.0
%
 
0.0
%
Expected volatility
74.9
%
 
77.2
%
Expected term (in years)
2.5

 
2.8


The following table presents a summary of changes in the fair value of the Company’s Level 3 financial liabilities for the three months ended March 31, 2020 and 2019:
 
Three Months Ended March 31,
 
2020
 
2019
Balance at beginning of the period
$
23,509

 
$
17,926

Loss recognized from the change in fair value of common stock warrants
1,922

 
12,746

Decrease in fair value from warrants exercised during the period
(141
)
 
(910
)
Balance at end of the period
$
25,290

 
$
29,762


Of the loss recognized from the change in fair value of common stock warrants for the three months ended March 31, 2020 and 2019, $1.9 million and $12.5 million, respectively, was attributable to the change in the unrealized loss related to warrants outstanding as of March 31, 2020 and 2019.
During the three months ended March 31, 2020 and 2019, the Company issued 2,115 shares and 18,285 shares of common stock, respectively, upon the exercise of Series A warrants issued in October 2017. As of March 31, 2020 and 2019, there were Series A warrants outstanding to purchase 415,200 shares and 492,500 shares, respectively, of the Company’s common stock (see Note 7, “Stockholders’ Equity”).
6. Leases
In February 2016, the FASB issued ASU No. 2016-02, Leases. The new standard and its related amendments (collectively referred to as ASC 842) requires lessees to recognize right-of-use assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. The new standard was effective for the Company starting in the first quarter of fiscal 2019. The Company adopted the new standard using the modified retrospective approach and recognized right-of-use leased assets and corresponding operating lease liabilities of $12.4 million on the consolidated balance sheet as of January 1, 2019. The Company did not restate prior periods. Deferred rent of $1.0 million and $3.8 million as of January 1, 2019 was reclassified from other current liabilities and deferred rent long-term, respectively, to a reduction of the right-of-use leased assets in connection with the adoption of the standard.
The Company’s leases consist primarily of operating leases for general office space, laboratory, manufacturing and warehouse facilities, and equipment. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. Because the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the lease Commencement Date in determining the present value of future lease payments. The Company used the incremental borrowing rate on January 1, 2019 for operating leases that commenced prior to that date. For lease agreements entered into or reassessed after the adoption of ASC 842, the Company combines lease and non-lease components.

13


Certain leases include an option to renew, with renewal terms that can extend the lease term for additional periods. The exercise of lease renewal options is at the Company’s sole discretion. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option that is reasonably certain to be exercised.
In January 2019, the Company entered into a lease agreement for approximately 25,332 square feet of additional general administrative office space (Initial Premises) located on Vista Sorrento Parkway, in San Diego, California (Vista Sorrento Lease). The lease term for the Initial Premises commenced in March 2019 and expires in September 2022. In May 2019, the Company entered into a First Amendment to the Vista Sorrento Lease (First Amendment) to expand the leased premises by adding approximately 33,681 square feet of additional general administrative office space (Expansion Space), and to extend the lease term for the Initial Premises through January 2023. The lease term for the Expansion Space commenced in May 2019 and expires in January 2023. The Company has a one-time option to extend the term of the Vista Sorrento Lease, covering both the Initial Premises and the Expansion Space, for a period of four years. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of $3.1 million on the consolidated balance sheet in the first quarter of 2019 related to the Initial Premises, and $4.7 million related to the First Amendment.
In November 2019, the Company entered into a lease agreement for approximately 94,562 square feet of additional general office space located on Shoreline Drive, in Boise, Idaho (Shoreline Lease). Subject to limited exceptions, the initial lease term is expected to begin on the earlier of (i) the date on which the Company substantially completes certain specified work related to tenant improvements, (ii) the date on which the Company begins use of the premises for their intended purpose, or (iii) July 1, 2020, and will expire 84 months from the first day of the first full month following the start of the lease term. The Company has a one-time option to extend the term of the Shoreline Lease for a period of three years. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $6.5 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020. Future minimum payments due under the Shoreline Lease are approximately $8.2 million as of March 31, 2020.
In January 2020, the Company entered into a sub-lease agreement for approximately 30,703 square feet of general office space located on High Bluff Drive, in San Diego, California (High Bluff Lease). The lease term begins in April 2020 and expires in March 2022. The Company recognized right-of-use leased assets and corresponding operating lease liabilities of approximately $2.3 million on the consolidated balance sheet on the Commencement Date in the first quarter of 2020. Future minimum payments due under the High Bluff Lease are approximately $2.4 million as of March 31, 2020.
The Company’s total lease cost recorded in the condensed consolidated statements of operations was $1.8 million and $0.7 million, respectively, for the three months ended March 31, 2020 and 2019, which included $1.7 million and $0.7 million, respectively, of operating lease cost and $0.1 million of short-term lease cost in 2020. Cash paid for amounts included in the measurement of lease liabilities, representing operating cash flows from operating leases, was $1.6 million and $0.9 million for the three months ended March 31, 2020 and 2019, respectively.

Maturities of operating lease liabilities at March 31, 2020 were as follows (in thousands):

Years Ending December 31,
 
 
2020 (remaining)
 
$
5,994

2021
 
9,422

2022
 
7,314

2023
 
3,388

2024
 
1,881

Thereafter
 
3,975

Total undiscounted lease payments
 
31,974

Less: amount representing interest
 
(4,107
)
Present value of operating lease liabilities
 
27,867

Less: current portion of operating lease liabilities
 
(8,320
)
Operating lease liabilities - long-term
 
$
19,547



14


As of March 31, 2020, the weighted average remaining lease term for operating leases was 4.1 years and the weighted-average discount rate used to determine the operating lease liabilities was 6.3%. As of December 31, 2019, the weighted average remaining lease term for operating leases was 3.6 years and the weighted-average discount rate used to determine the operating lease liabilities was 6.6%.
7. Stockholders’ Equity
Shares Reserved for Future Issuance

The following shares of the Company’s common stock were reserved for future issuance as of March 31, 2020 (in thousands):

Shares underlying outstanding warrants
705

Shares underlying outstanding stock options
6,684

Shares authorized for future equity award grants
2,961

Shares authorized for issuance pursuant to awards granted under the ESPP
1,692

 
12,042



Common Stock Warrants

As of March 31, 2020, there were Series A warrants outstanding to purchase 415,200 shares of the Company’s common stock at an exercise price of $3.50 per share, which were issued in connection with a financing in October 2017, and which expire in October 2022. Also outstanding as of March 31, 2020, were warrants to purchase 193,788 shares of the Company’s common stock at an exercise price of $23.50 per share, which were issued in March 2017, and which expire in March 2027, and warrants to purchase 95,781 shares of the Company’s common stock at an exercise price of $73.73 per share, which were issued between August 2011 and August 2012, and which expire between August 2021 and August 2022. The Company issued 2,320 shares of its common stock upon the exercise of warrants during the three months ended March 31, 2020, and 18,285 shares of its common stock upon the exercise of warrants during the three months ended March 31, 2019.

Stock Plans
The Company issued 672,442 and 408,964 shares, respectively, of its common stock upon the exercise of stock options during the three months ended March 31, 2020 and 2019.
The ESPP enables eligible employees to purchase shares of the Company’s common stock using their after-tax payroll deductions, subject to certain conditions. Generally, offerings under the ESPP consist of a two-year offering period with four six-month purchase periods which begin in May and November of each year. There were no shares of common stock purchased under the ESPP in the three months ended March 31, 2020 and 2019.
Stock-Based Compensation
The Company granted options to purchase 229,911 shares and 1,294,053 shares of common stock, respectively, under the 2013 Plan during the three months ended March 31, 2020 and 2019. These options have an exercise price equal to the closing price of the Company’s common stock on the applicable award date, and generally vest as to 25% of the underlying shares on the first anniversary of the award, with the balance of the options vesting monthly over the following three years.
In addition, during the three months ended March 31, 2019, the Company awarded stock options to purchase 1,035,000 shares of common stock, which were subject to and conditioned upon the approval by its stockholders of an increase in the number of shares of common stock reserved for issuance under our 2013 Plan prior to December 31, 2019. No stock-based compensation expense was recognized for these contingent stock option grants during the three months ended March 31, 2019, because the approval by our stockholders of the increase in the number of shares of common stock reserved for issuance under our 2013 Plan did not occur until June 2019.

15


The assumptions used in the Black-Scholes option-pricing model are as follows:
 
Stock Options
Three Months Ended
March 31,
2020
 
2019
Weighted average grant date fair value (per share)
$43.40
 
$32.51
Risk-free interest rate
1.1
%
 
2.5
%
Expected dividend yield
0.0
%
 
0.0
%
Expected volatility
72.5
%
 
71.6
%
Expected term (in years)
6.1

 
6.1


The Company records stock-based compensation expense associated with the ESPP using the Black-Scholes option-pricing model. Valuations are performed on the grant date at the beginning of the purchase period, which generally occurs in May and November of each year.
The following table summarizes the allocation of stock-based compensation expense included in the consolidated statement of operations (in thousands):
 
Three Months Ended
March 31,
 
2020
 
2019
Cost of sales
$
2,164

 
$
1,139

Selling, general & administrative
11,501

 
7,000

Research and development
2,200

 
1,695

Total
$
15,865

 
$
9,834


The total stock-based compensation expense capitalized as part of the cost of the Company’s inventories was $1.3 million and $1.3 million as of March 31, 2020 and December 31, 2019, respectively.

8. Income Taxes
For the three months ended March 31, 2020, the Company’s income tax expense is primarily attributable to state and foreign income tax expense as a result of current taxable income in those jurisdictions. The Company used the year-to-date effective tax rate method to determine its interim income tax expense for federal and state jurisdictions where a reliable estimate of the annual effective tax rate could not be made.

The Company maintains a full valuation allowance against its net deferred tax assets as of March 31, 2020 based on the current assessment that it is not more likely than not these future benefits will be realized before expiration.

On March 27, 2020, the United States enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act). The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the United States economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions which are expected to impact the Company’s financial statements include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Due to the recent enactment of the CARES Act, the Company is unable to quantify the impact, if any, that the CARES Act will have on its financial position, results of operations or cash flows but it is not anticipated to be significant.


16


9. Commitments and Contingencies
Legal and Regulatory Matters
From time to time, the Company may be subject to legal proceedings or regulatory matters arising in the ordinary course of business, including actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any legal proceeding or regulatory matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome. As of March 31, 2020 and December 31, 2019, there were no legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the outcome, legal proceedings, regulatory matters, and other disputes and claims can have an adverse impact on the Company because of legal costs, diversion of management time and resources, and other factors.

17


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis together with our financial statements and related notes in Part I, Item 1 of this Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (Quarterly Report).
This Quarterly Report contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to considerable risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements included or incorporated by reference in this Quarterly Report, other than statements of historical fact, are forward-looking statements. You can identify forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements. In particular, forward-looking statements contained in this Quarterly Report may relate to, among other things, our future or assumed financial condition, results of operations, liquidity, business forecasts and plans, research and product development plans, manufacturing plans, strategic plans and objectives, capital needs, financing plans and objectives, product launches, distribution plans, clinical trials, regulatory approvals and competitive environment. We caution you that the foregoing list may not include all of the forward-looking statements made in this Quarterly Report.
Our forward-looking statements are based on our management’s current assumptions and expectations about future events and trends, which affect or may affect our business, strategy, operations or financial performance. Although we believe that these forward-looking statements are based upon reasonable assumptions, they are subject to numerous known and unknown risks and uncertainties and are made in light of information currently available to us. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below in the section entitled “Risk Factors” in Part II, Item 1A, and elsewhere in this Quarterly Report, as well as the other public filings we make with the Securities and Exchange Commission. In particular, as discussed in greater detail below, our financial condition and results could be materially adversely affected by the impacts and disruptions caused by the novel coronavirus (COVID-19) global pandemic. You should read this Quarterly Report with the understanding that our actual future financial condition and results may be materially different from and worse than what we expect.
Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
Forward-looking statements speak only as of the date they were made, and, except to the extent required by law or the rules of the NASDAQ Global Market, we undertake no obligation to update or review any forward-looking statement because of new information, future events or other factors.
We qualify all of our forward-looking statements by these cautionary statements.
Overview
We are a medical device company with an innovative approach to the design, development and commercialization of products for people with insulin-dependent diabetes. Our goal is to lead in insulin therapy management by building a robust ecosystem and portfolio of data-driven products and services around our flagship insulin pumps. We believe our competitive advantage is rooted in our consumer-focused approach, and the incorporation of modern and innovative technology into our product offerings. Our manufacturing, sales and support activities principally focus on our flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), which is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen, as well as our complementary product offerings, such as our t:connect data management application (t:connect) and the Tandem Device Updater. We aim to improve and simplify the lives of people with diabetes and those of their healthcare providers, by delivering innovative hardware and software solutions, as well as best-in-class customer support.

18


Since our initial commercial launch, we have been able to rapidly innovate and bring more products to market than our competitors. We have commercially launched seven insulin pumps in the United States since 2012, two of which we also launched outside the United States since 2018. Four of our insulin pumps have featured integration with CGM technology, of which two have also featured an automated insulin delivery (AID) algorithm. The United States Food and Drug Administration (FDA) has defined requirements for the interoperability of devices as a complete AID system, which we believe will help support continued rapid innovation by streamlining the regulatory pathway for integrated products. This interoperability designation is comprised of three categories: alternate controller enabled (ACE) infusion pumps, integrated continuous glucose monitor (iCGM) devices, and interoperable automated glycemic controller (iAGC) technology. In June 2018, the t:slim X2 was the first insulin pump designated as compatible with iCGM devices; in February 2019 the t:slim X2 was the first insulin pump to receive ACE pump designation, and in December 2019 our Control-IQ technology for the t:slim X2 was cleared as the first iAGC.
In the four-year period ended March 31, 2020, we shipped approximately 155,000 insulin pumps, which is representative of our estimated global installed customer base, assuming the typical four-year reimbursement cycle. Approximately 127,000 of these pumps were shipped to customers in the United States and approximately 28,000 were shipped to international markets.
Today, our t:slim X2 hardware platform represents 100% of our new pump shipments. The simple-to-use t:slim X2 is the smallest durable insulin pump available, and the only commercial insulin pump that allows users to update their pumps’ software quickly and easily from a personal computer using our revolutionary Tandem Device Updater tool. This unique offering positions us to bring future innovations, including our next generation AID algorithms, to our in-warranty t:slim X2 customers faster than the industry has been able to in the past and independent of the typical four-year insurance pump reimbursement cycle. We have offered in-warranty t:slim customers in the United States four different software updates for no-cost since the Tandem Device Updater was approved in July 2016, including our two AID algorithms, Basal-IQ technology and Control-IQ technology. Basal-IQ technology launched in August 2018 and is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. Control-IQ technology launched in January 2020 and is an advanced hybrid-closed loop feature, designed to help increase a user’s time in targeted glycemic range. It is the first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. Outside the United States we began selling efforts with t:slim X2 with Dexcom G5 CGM integration in the third quarter of 2018, offering no-cost software updates for Basal-IQ technology in the third quarter of 2019, and intend to begin offering Control-IQ technology updates in select geographies in the second half of 2020, subject to required regulatory and reimbursement approvals.
Our insulin pump products are generally considered durable medical equipment and have an expected lifespan of at least four years. In addition to insulin pumps, we sell disposable products that are used together with our pumps and are replaced every few days, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to a user’s body.
For the three months ended March 31, 2020 and 2019, our consolidated sales were $97.9 million and $66.0 million, respectively. For the three months ended March 31, 2020 and 2019, our net loss was $14.9 million and $23.0 million, respectively. Worldwide pump sales accounted for 61% and 70% of our total sales, respectively, for the three months ended March 31, 2020 and 2019, while pump-related supplies and accessories accounted for the remainder in each year. Our accumulated deficit as of March 31, 2020 and December 31, 2019 was $639.7 million and $624.8 million, respectively. These amounts included $234.4 million and $216.6 million of accumulated non-cash stock-based compensation charges and non-cash charges from the change in fair value of common stock warrants as of March 31, 2020 and December 31, 2019, respectively.

19


In the United States, we have rapidly increased sales since the commercial launch of our first product by expanding our sales, clinical and marketing organization, by developing, commercializing and marketing multiple differentiated products that utilize our proprietary technology platform and consumer-focused approach, and by providing strong customer support. Our sales have further increased following our scaled product launches in geographies outside of the United States. We believe that by demonstrating our product benefits and the shortcomings of existing insulin therapies, more people will choose our insulin pumps for their therapy needs, allowing us to further penetrate and expand the market worldwide. In addition, we believe publications, such as the results from the study using Control-IQ technology that was published in the New England Journal of Medicine in October 2019, will be valuable in demonstrating the clinical outcome benefits derived from our system to healthcare providers and payors. We also believe we are positioned well to address consumers’ needs and preferences with our current products and products under development and by offering customers access to our future innovations through the Tandem Device Updater, as they are approved by the local regulating bodies. At the same time, by innovating and offering new product features and benefits using our t:slim X2 platform, we are able to leverage a shared global manufacturing and supply chain infrastructure. In the United States, we are able to leverage a single sales, marketing, and clinical organization, as well as our domestic customer support services. In Canada, we have a separate sales organization and our customer support infrastructure benefits from close collaboration with our United States organization. In other international geographies, we have contracted with experienced distribution partners to commercialize and support our t:slim X2 platform.
COVID-19 Impact and Considerations
We are deemed an essential healthcare business under applicable governmental orders based on the critical nature of the products we offer and the community we serve. During the first quarter of 2020, we experienced a modest impact from the COVID-19 global pandemic. However we anticipate that our sales and operating results will be adversely impacted in the coming months. We currently anticipate our sales outside the United States may experience a greater proportional impact due to differences in the sales process in domestic versus international markets. Additionally, the initiation of certain programs planned for the second quarter, such as human factors studies associated with our product development efforts, will likely be delayed. The full extent of the impact of COVID-19 on our business and operations is currently not estimable and will depend on a number of factors including the scope and duration of the global pandemic.
We have taken steps to prioritize the health and safety of our employees and customers during this pandemic, while working to maintain a continuous supply of products, training and customer support. To that end, we have increased the frequency of our communications to employees, suppliers, customers, and healthcare providers. In March 2020, we restricted non-essential employee travel, banned visitors from all of our facilities, and transitioned those employees able to perform their job function outside of our facilities to a remote work environment. For our field-based sales and clinical employees, we have discontinued in-person activities and are utilizing technology to remotely engage healthcare providers and customers. For our employees in manufacturing and warehousing positions involved in production and fulfillment operations, we have implemented preventative measures to comply with social distancing requirements and have taken measures to help ensure safety, including requiring temperature checks for our employees before each shift.
In response to developments surrounding the COVID-19 global pandemic, we initiated discussions with our key suppliers in early 2020 regarding their abilities to fulfill existing orders, and we have continued to regularly assess their capacity. At this time, we believe many of our suppliers are deemed essential businesses under applicable governmental orders, and we do not anticipate disruption in our ability to manufacture insulin pumps and cartridges due to component procurement limitations. Our finished goods and raw material inventory for insulin pumps, as well as available manufacturing capacity, meet or exceed our target levels and position us well to respond to unforeseen disruptions in the near term.
More recently, we observed customers purchasing cartridges and infusion sets at a higher rate than anticipated. Currently, our inventory for finished cartridges and infusion sets is below our targeted level. Near the end of the first quarter, our third-party cartridge manufacturer completed validation and commenced commercial-scale manufacturing to supplement our existing cartridge manufacturing capacity, which we believe will assist us in meeting product demand and allow us to build inventory levels in line with our targets. In addition, our primary infusion set manufacturer is currently working through inventory constraints and we have asked some customers to accept substitutions of similar products to prevent delays in order fulfillment. We are carefully managing our pump supplies inventory while we work to overcome these temporary challenges.
Commercially, we have been communicating with our customers and healthcare providers through social media, direct email outreach and our website, in addition to the regular communications from the supporting sales and clinical employees. We are leveraging the availability of our technology platforms, such as our t:connect diabetes management application, to support healthcare providers as many of them are expanding telehealth capabilities in their practices. By the end of the first quarter, we also expanded our remote new pump training offering to 100% of customers who purchase a t:slim X2 insulin pump.

20


We are prudently managing our use of cash and we believe that our total cash and investments on hand are sufficient to sustain our existing operations for at least the next 12 months from the date of this filing. In the meantime, we are focused on making necessary investments in the organization as originally planned to continue to progress against our long-term sales and profitability initiatives, including recruitment of key employees, advancement of the R&D pipeline and implementation of technology solutions. We will continue to evaluate our business operations based on new information as it becomes available and we intend to make changes that we consider necessary in light of this information.
Products Under Development
Our products under development support our strategy of focusing on both consumer and clinical needs, and include AID system enhancements, a connected (mobile) health offering and a next-generation hardware platform, which we refer to as the t:sport Insulin Delivery System (t:sport). We intend to leverage our consumer-focused approach and proprietary technology platform to continue to develop products that have the features and functionality that will allow us to meet the needs of people in differentiated segments of the insulin-dependent diabetes market, including the following:
t:sport Insulin Delivery System - Approximately half the size of our t:slim X2 pump, the t:sport pump is being designed for people who seek even greater discretion and flexibility with the use of their insulin pump. We anticipate that t:sport will feature a 200-unit cartridge, an on-pump bolus button, a rechargeable battery, an AID algorithm, and a Bluetooth radio. t:sport is being designed for use with leading U-100 insulins, and we are evaluating the use of insulin concentrates to provide to people with greater insulin needs. We anticipate that t:sport will be our first insulin pump to support full pump-control from our mobile application, subject to FDA review and approval. A separate controller may be offered in addition to or in advance of full mobile control availability.
Connected (Mobile) Health Offerings – We began a limited launch in the first quarter of 2020 and we are preparing for a full commercial launch in the second quarter of a mobile application that has been designed to utilize the Bluetooth radio integrated with the t:slim X2 to wirelessly upload pump data to the cloud-based t:connect diabetes management application, receive notification of pump alerts and alarms, and provide a discrete, secondary display of glucose and insulin data.  Future updates of this app will integrate other health-related information from third-party sources and support future pump-control capabilities for our products under development.
The launch of the first generation of this app in the United States allows for the wireless upload of data to t:connect and is intended to reduce patient burden and increase healthcare provider office efficiency by reducing the manual steps historically required for data extraction.
Over time, we also intend to offer additional features and enhancements to the mobile application, including partial or full control of pump features.
Pump Shipments
From inception through June 2018, we derived nearly all of our sales from the shipment of insulin pumps and associated supplies to customers in the United States. Starting in the third quarter of 2018, we commenced sales of our t:slim X2 insulin pump in select international geographies. We consider the number of insulin pump units shipped per quarter domestically and internationally to be an important metric for managing our business.
In the four-year period ended March 31, 2020, we shipped approximately 155,000 insulin pumps, of which approximately 127,000 were shipped to customers in the United States and approximately 28,000 were shipped to international markets. In the first quarter of 2020, we shipped 17,378 insulin pumps worldwide compared to 14,732 insulin pumps shipped in the first quarter of 2019.

21


Pump shipments to customers in the United States by fiscal quarter were as follows:
 
Pump Units Shipped for Each of the Three Months Ended in Respective Years - U.S.
 
March 31
 
June 30
 
September 30
 
December 31
 
Total
2012

 
9


204

 
844

 
1,057

2013
852

 
1,363

 
1,851

 
2,406

 
6,472

2014
1,723

 
2,235

 
2,935

 
3,929

 
10,822

2015
2,487

 
3,331

 
3,431

 
6,234

 
15,483

2016
4,042

 
4,582

 
3,896

 
4,418

 
16,938

2017
2,816

 
3,427

 
3,868

 
6,950

 
17,061

2018
4,444

 
5,447

 
7,379

 
12,935

 
30,205

2019
9,669

 
12,799

 
13,814

 
17,453

 
53,735

2020
13,158

 
N/A

 
N/A

 
N/A

 
13,158

Pump shipments to international customers by fiscal quarter were as follows:
 
Pump Units Shipped for Each of the Three Months Ended in Respective Years - International
 
March 31
 
June 30
 
September 30
 
December 31
 
Total
2018
N/A

 
N/A

 
1,055

 
3,233

 
4,288

2019
5,063

 
8,459

 
4,025

 
2,149

 
19,696

2020
4,220

 
N/A

 
N/A

 
N/A

 
4,220

Trends Impacting Financial Results
Overall, we have experienced considerable sales growth since the commercial launch of our first product in the third quarter of 2012, while incurring operating losses since our inception. Our operating results have historically fluctuated on a quarterly or annual basis, particularly in periods surrounding anticipated regulatory approvals, the commercial launch of new products by us and our competitors, the commercial launch of our products in geographies outside of the United States and due to general seasonality in the United States. We expect these periodic fluctuations in our operating results to continue.
We believe that our financial condition and operating results, as well as the decision-making process of our current and potential customers, has been and will continue to be impacted by a number of general trends, including the following:
market acceptance of our products and competitive products by people with insulin-dependent diabetes, their caregivers and healthcare providers;
the introduction of new products, treatment techniques or technologies for the treatment of diabetes, including the timing of the commercialization of new products by us and our competitors;
seasonality in the United States associated with annual insurance deductibles and coinsurance requirements associated with the medical insurance plans utilized by our customers and the customers of our distributors;
incidence of disease or illness, including regional or global pandemics that may impact customer purchasing patterns or disrupt our supply chain;
timing of holidays and summer vacations, which may vary by geography;
the buying patterns of our distributors and other customers, both domestically and internationally;
changes in the competitive landscape, including as a result of companies entering or exiting the diabetes therapy market;

22


access to adequate coverage and reimbursement for our current and future products by third-party payors, and reimbursement decisions by third-party payors;
the magnitude and timing of any changes to our facilities, manufacturing operations and other infrastructure, and factors impacting our ability to access our facilities;
the impact of any privacy breaches, which may subject us to legal and regulatory proceedings and substantial fines, penalties and expenses, as well as significant reputational harm;
anticipated and actual regulatory approvals of our products and competitive products; and
product recalls impacting, or the suspension or withdrawal of regulatory clearance or approval relating to, our products or the products of our competitors.
In addition to these general trends, we believe the following specific factors have materially impacted, and could continue to materially impact our business going forward:
the disruptions caused by the COVID-19 global pandemic on suppliers, third-party manufacturers, healthcare providers, distributors and our existing or potential customers;
continued increase in demand following the commercial launch of t:slim X2 and the demonstrated success of our Tandem Device Updater;
anticipated new product launches;
increased opportunity to achieve customer renewals as customers become eligible for insurance reimbursement to purchase a new insulin pump at the end of the typical four-year reimbursement cycle;
opportunity to transition former customers of Animas Corporation (Animas) to our t:slim X2 insulin pump in 2018 and 2019 following the announcement by Johnson & Johnson that it had discontinued the operations of Animas and discontinued the availability of Animas pump supplies in September 2019;
designation by UnitedHealthcare of one of our competitors as its preferred, in-network durable medical equipment provider of insulin pumps for most customers age seven and above;
ability to enter into and maintain agreements with CGM partners for CGM integration;
expansion and new product launches in select international geographies, including initial orders to stock inventories; and
ability to effectively scale our operations to support rapid growth, including expanding our facilities, advancing our research and development efforts, increasing manufacturing capacity through third-party manufacturers, and hiring and retaining employees in customer service and support functions.

In addition to working to achieve our sales growth expectations, we intend to continue to leverage our infrastructure investments to realize additional manufacturing, sales, marketing and administration cost efficiencies with the goal of improving our operating margins and ultimately achieving sustained profitability. We achieved profitability for the first time in the fourth quarter of 2018, and again in the fourth quarter of 2019, though we may be unable to achieve profitability consistently from period to period. We believe we can ultimately achieve sustained profitability by driving incremental sales growth in U.S. and international markets, meeting our pump renewal sales objectives, maximizing manufacturing efficiencies on increased production volumes, and leveraging the investments made in our sales, clinical, marketing and customer support organizations.


23


Recent Developments
Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States
In January 2020, we began shipping our t:slim X2 insulin pumps pre-loaded with Control-IQ technology, an advanced hybrid-closed loop feature designed to help increase time in range (70-180 mg/dL), to new customers in the United States. The t:slim X2 is the first and only system cleared to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar. The system integrates with the Dexcom G6 CGM. In addition, we communicated the availability of Control-IQ technology to all of our in-warranty t:slim X2 customers in the United States, who have the option to add the new feature free of charge via the Tandem Device Updater. Customers interested in the remote software update are first required to obtain a prescription from their healthcare provider and complete a set of online training modules.
FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller
In February 2020, the FDA cleared our Basal-IQ technology as an iAGC. This is the second system to receive iAGC designation by the FDA, following the Company’s clearance of the t:slim X2 insulin pump with Control-IQ technology in December 2019.
Cartridge Manufacturing Commences at Third-Party Contract Manufacturer
In the first quarter of 2020, we outsourced a portion of our cartridge manufacturing demand to an experienced third-party contract manufacturer. We believe our relationship with this contract manufacturer provides us additional flexibility in scaling our business and also mitigates some risk of having only a single site for cartridge manufacturing. We anticipate that this new manufacturing model will enable us to significantly increase our cartridge manufacturing capacity in the long term, without meaningfully increasing the cost of overhead associated with our manufacturing facilities.

Components of Results of Operations
Sales
We offer products for people with insulin-dependent diabetes. We commenced commercial sales of our original t:slim insulin pump platform in the United States in the third quarter of 2012 and continued to launch various iterations of that platform during the following years. In October 2016, we began shipping our flagship pump platform, the t:slim X2 insulin pump. The t:slim X2 insulin pump platform with advanced software algorithms and remote software update capabilities, now represents 100% of our new pump shipments. Accordingly, in the third quarter of 2018 we discontinued new sales of all prior platform versions. Our products also include disposable cartridges and infusion sets, as well as our complementary t:connect and Tandem Device Updater products. In addition, we offer accessories including protective cases, belt clips, and power adapters, although sales of these products are not significant.
We primarily sell our products through national and regional distributors in the United States on a non-exclusive basis. These distributors are generally providers of medical equipment and supplies to individuals with diabetes. Our primary end customers are people with insulin-dependent diabetes. Similar to other durable medical equipment, the primary payor is generally a third-party insurance carrier and the customer is usually responsible for any medical insurance plan copay or coinsurance requirements. We believe our existing sales, clinical, and marketing infrastructure will allow us to continue to increase sales by allowing us to promote our products to a greater number of potential customers, caregivers and healthcare providers, although the COVID-19 global pandemic may have a material adverse impact on our sales in future periods.
In the third quarter of 2018, we began the launch of our t:slim X2 with Dexcom G5 CGM integration through distribution partners outside the United States, including in select European countries, Australia, New Zealand, and South Africa. During the second quarter of 2019, we began selling our t:slim X2 with Basal-IQ technology in certain of these geographies. In the first quarter of 2020, we delivered initial orders to support launches in Germany and France that are expected to occur in the second quarter of 2020. Our independent distributor partners perform all sales, customer support and training in their respective markets. In Canada, we market with a direct sales force and, similar to the United States, use a distributor partner for certain billing and fulfillment activities. Historically, we have experienced consistent levels of reimbursement for our products in the United States, but we expect the average sales price will vary in international markets based on a number of factors, such as the geographical mix, nature of the reimbursement environment, government regulations and the extent to which we rely on distributor relationships to provide sales, clinical and marketing support.

24


In general, in the United States we have experienced pump shipments being weighted heavily towards the second half of the year, with the highest percentage of pump shipments expected in the fourth quarter due to the nature of the reimbursement environment. Consistent with our historical seasonality, domestic pump shipments from the fourth quarter to the following first quarter decrease significantly. Internationally, we do not expect this same impact from seasonality associated with reimbursement, although the quarterly sales trends may be impacted by a number of factors, including summer vacations and launches into new geographies. While the opportunity to transition former Animas customers positively impacted our 2019 quarterly sales trends worldwide, we do not anticipate that this trend will continue to have a significant impact.
In the first quarter of 2020, the COVID-19 global pandemic had a major impact on businesses around the world. Although we experienced only a modest impact on our first quarter financial results, in March 2020 we ceased in-person sales, marketing and training activities and adopted numerous other changes to our daily business operations. These changes remain in effect as of the date of this report and it remains uncertain when we may be able to resume our normal operations. Accordingly, we anticipate that our sales will not follow historical trends and will be adversely impacted in the coming months as customers delay their purchasing decisions or physicians pause their prescriptions of new products. Our sales outside the United States may experience a greater proportional impact due to differences in the sales process in domestic versus international markets. The full extent of the impact of COVID-19 on our business and operations will depend on a number of factors, including the depth and duration of the global pandemic.
Separate of any impacts from COVID-19, our quarterly sales have historically fluctuated, and may continue to fluctuate, substantially in the periods surrounding anticipated and actual regulatory approvals and commercial launches of new products by us or our competitors. We believe customers may defer purchasing decisions if they believe a new product may be launched in the future. Additionally, upon the announcement of FDA approval or commercial launch of a new product, either by us or one of our competitors, potential new customers may reconsider their purchasing decisions or take additional time to consider such FDA approval or product launch before making their purchasing decisions. For instance, we believe certain customers paused their decision-making during the second half of 2019 in anticipation of the commercial availability of the t:slim X2 with Control-IQ technology. However, it is difficult to quantify the extent of the impact of these or similar events on future purchasing decisions.
Cost of Sales
Historically, we have manufactured our pumps and disposable cartridges at our manufacturing facility in San Diego, California. Near the end of the first quarter, our third-party cartridge manufacturer completed validation and commenced commercial-scale manufacturing to supplement our existing cartridge manufacturing capacity. Infusion sets and pump accessories are manufactured by third-party suppliers. Cost of sales includes raw materials, labor costs, manufacturing overhead expenses, product training costs, royalties, freight, reserves for expected warranty costs, scrap and charges for excess and obsolete inventories. Manufacturing overhead expenses include expenses relating to quality assurance, manufacturing engineering, material procurement, inventory control, facilities, equipment, information technology and operations supervision and management. We anticipate that our cost of sales will continue to increase as our product sales increase.
Over the long term, we expect our overall gross margin percentage, which for any given period is calculated as sales less cost of sales divided by sales, to improve, as our sales increase and our overhead costs are spread over larger production volumes. We expect we will be able to leverage our manufacturing cost structure across our products that utilize the same technology platform and manufacturing infrastructure and will be able to further reduce per unit costs with increased automation, process improvements and raw materials cost reductions. Pumps have, and are expected to continue to have, a higher gross margin percentage than our pump-related supplies. Therefore, the percentage of pump sales relative to total sales will have a significant impact on our overall gross margin percentage. In the event that customers delay their pump purchasing decisions or physicians pause in prescribing new pumps as a result of COVID-19, or for other reasons, it is possible that we may experience a higher percentage of pump-related supply sales than anticipated, which in turn could adversely impact our overall gross margin percentage. We also expect our warranty cost per unit to decrease as we release additional product features and functionality utilizing the Tandem Device Updater. However, our overall gross margin percentage may fluctuate in future quarterly periods as a result of numerous factors aside from those associated with production volumes and product mix. For instance, as a result of COVID-19 we have implemented operational changes that may introduce unpredictable variability to our cost of sales, such as incremental expenses to protect the health, safety and welfare of our employees working on-site and to enable other employees to work remotely. In addition, as demand for our products increases, we may continue to make additional investments in manufacturing capacity or increase our reliance on third parties for manufacturing-related services, either of which could have a negative impact on our gross margins in the near-term. Specifically, in 2020, we are investing in additional manufacturing equipment to meet anticipated long-term demand for our cartridges, which may initially place downward pressure on the gross margin percentage associated with our pump-related supplies.

25


Other factors impacting our overall gross margin percentage may include the changing percentage of products sold to distributors versus directly to individual customers, varying levels of reimbursement among third-party payors in domestic and international markets, the timing and success of new regulatory approvals and product launches, the impact of the valuation and amortization of employee stock option grants on non-cash stock-based compensation expense allocated to cost of sales, changes in warranty estimates, training costs, licensing and royalty costs, cost associated with excess and obsolete inventories, and changes in our manufacturing processes, capacity, costs or output.
Selling, General and Administrative
Our selling, general and administrative (SG&A) expenses primarily consist of salary, cash-based incentive compensation, fringe benefits and non-cash stock-based compensation for our executive, financial, legal, marketing, sales, clinical, customer support, technical services, insurance verification, regulatory affairs and other administrative functions. We began expanding our U.S. field sales and clinical organization during the third quarter of 2019 to support an expected increase in demand for our products. We had approximately 90 sales territories as of March 31, 2020. Our existing territories are generally maintained by sales representatives and field clinical specialists, and supported by managed care liaisons, additional sales management and other customer support personnel, which have also been rapidly expanding to support our growing installed base. Our operations in Canada are comprised of approximately 10 sales territories. Other significant SG&A expenses include those incurred for product demonstration samples, commercialization activities associated with new product launches, travel, trade shows, outside legal fees, independent auditor fees, outside consultant fees, insurance premiums, facilities costs and information technology costs. Overall, we expect our SG&A expenses, including the cost of our customer support infrastructure, to increase as our customer base grows in the United States and international markets. We will continue to evaluate, and may further increase, the number of our field sales and clinical personnel in order to optimize the coverage of our existing territories. Additionally, we realized a notable increase in non-cash stock-based compensation expense allocated to SG&A beginning in the third quarter of 2018, and again in the second quarter of 2019, due to the valuation of certain employee stock option grants and the impact on the valuation from the significant increase in our stock price over the previous year. We expect higher non-cash stock-based compensation expense will be sustained through the first half of 2020 and will begin to decline in future quarters. Our SG&A expenses may be affected by our response to the COVID-19 global pandemic, including reduced spending in areas such as non-essential employee travel, which may be offset by increased spending to support measures designed to prioritize the retention, health, safety and welfare of our employees. In the longer term, SG&A expenses may also increase due to anticipated costs associated with additional compliance and regulatory reporting requirements.
Research and Development
Our research and development (R&D) activities primarily consist of engineering and research programs associated with our products under development, as well as activities associated with our core technologies and processes. R&D expenses are primarily related to employee compensation, including salary, fringe benefits, non-cash stock-based compensation and temporary employee expenses. We also incur R&D expenses for supplies, development prototypes, outside design and testing services, depreciation, allocated facilities and information services, clinical trial costs, payments under our licensing, development and commercialization agreements and other indirect costs. We expect our R&D expenses to increase as we advance our products under development and develop new products and technologies, partially offset by future expected declines in non-cash stock-based compensation. Similar to our SG&A expenses, our future R&D spending may be impacted by the COVID-19 global pandemic. For instance, we may experience lower spending associated with delays in the advancement of particular programs, which may be offset by increased spending to support the retention, health, safety and welfare of our employees.
Other Income and Expense

Other income and expense primarily consists of changes in the fair value of certain warrants issued in our public offering of common stock in October 2017, and interest earned on our cash equivalents and short-term investments. We expect other income and expense to fluctuate from period to period primarily due to the revaluation of the outstanding Series A warrants, which expire in the fourth quarter of 2022.


26


Results of Operations
 
Three Months Ended
March 31,
(in thousands, except percentages)
2020
 
2019
Sales:
 
 
 
Domestic
$
79,546

 
$
54,655

International
18,380

 
11,340

Total sales
97,926

 
65,995

Cost of sales
47,665

 
32,642

Gross profit
50,261

 
33,353

Gross margin
51
%
 
51
%
Operating expenses:
 
 
 
Selling, general and administrative
49,717

 
34,961

Research and development
14,117

 
9,389

Total operating expenses
63,834

 
44,350

Operating loss
(13,573
)
 
(10,997
)
Other income (expense), net:
 
 
 
Interest and other income
726

 
757

Interest and other expense

 
(6
)
Change in fair value of common stock warrants
(1,922
)
 
(12,746
)
Total other expense, net
(1,196
)
 
(11,995
)
Loss before income taxes
(14,769
)
 
(22,992
)
Income tax expense
98

 

Net loss
$
(14,867
)
 
$
(22,992
)
Comparison of the Three Months Ended March 31, 2020 and 2019
Sales. For the three months ended March 31, 2020, sales were $97.9 million, which included $18.4 million of international sales. Sales were $66.0 million for the same period in 2019, which included $11.3 million of international sales.
The increase in total sales of $31.9 million was primarily driven by an 18% increase in worldwide pump shipments to 17,378 in the first quarter of 2020 compared to 14,732 in the first quarter of 2019, and a 93% increase in pump-related supply sales. Sales of pump-related supplies increased primarily due to a 61% increase in our estimated installed base of customers, as well as a more recent trend of customers purchasing cartridges and infusion sets at a higher rate than anticipated, which we believe may be associated with COVID-19.

Domestic sales by product were as follows (in thousands):
 
Three Months Ended
March 31,
 
2020
 
2019
Pump
$
49,719

 
$
36,903